AstraZeneca's antiplatelet drug Brilinta has met its objectives in a 21,000-patient Phase III trial that could help the company meet its lofty ambitions for the drug. Updated results from the ...
The FDA has granted a fast review of AstraZeneca’s cardiovascular diseases drug Brilinta (ticagrelor) in the new indication that aims to reduce the chances of patients having recurring strokes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback